Almac Sciences has this year announced details of its “First in Man” approach to peptide synthesis. This embraces and offers development of peptide synthesis, full analytical support (including method ...

Almac is pleased to announce the expansion of our drug product Pharmaceutical Development services with the creation of a new non-GMP formulation development facility and two new analytical ...

Craigavon, N.I., UK, - 09 November 2015 - Almac Group, the global contract development and manufacturing organisation, has confirmed a £16 million investment to expand its formulation and analytical ...

Almac has created a new non-GMP formulation development facility and two new analytical laboratories at their U.K. headquarters in Craigavon to expand its drug product pharmaceutical development ...

Almac Group has completed a multi-million-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK. The significant investment by Almac Pharma Services, will ...

To win at the drug development game, it’s not enough to show up with a great molecule. Many compounds would stall at the discovery stage without effective ways to get them inside patients. But the ...

Following the success of one of its key client partnered products, Craigavon-based pharmaceutical company Almac, has announced the commercial manufacturing expansion. Together with the recent ...

When AstraZeneca ($AZN) abandoned its campus in Charnwood in the U.K. some years back, it left new owners to figure out what would be done with the facilities. Now ...

This investment is additional to and separate from £11 million that was announced in the fall of 2024 for creating new jobs and expanding Almac’s global analytical services capabilities. Almac ...

Almac Sciences, a member of the Almac Group, said today it has expanded its suite of analytical solutions to include biologics testing solutions. The company said its services will now include, in ...

Almac and VTU Technology have announced their collaboration to offer joint services for the expression of recombinant proteins with site-specific modification and labelling, such as PEGylation for ...

TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, a ...